The United Laboratories International Holdings Limited (HKG:3933)

Market Cap	17.12B -28.6%
Revenue (ttm)	14.70B -4.0%
Net Income	2.32B -21.6%
EPS	1.23 -24.4%
Shares Out	1.97B
PE Ratio	7.05
Forward PE	10.14
Dividend	0.49 (5.60%)
Ex-Dividend Date	Jul 7, 2026

Volume	8,494,000
Open	8.68
Previous Close	8.68
Day's Range	8.25 - 8.68
52-Week Range	8.32 - 17.98
Beta	0.31
Analysts	Strong Buy
Price Target	15.64 (+85.53%)
Earnings Date	Jun 11, 2026

About HKG:3933

The United Laboratories International Holdings Limited, an investment holding company, engages in the research and development, manufacture, distribution, and sale of pharmaceutical products. It operates through three segments: Bulk Medicine, Intermediate Products, and Finished Products. The company offers amoxicillin products; insulin series, antibiotics, and ophthalmic products; and veterinary drugs. It also provides 6-aminopenicillanic acid and penicillin G potassium products. In addition, the company provides endocrine and metabolism, anti-...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1990
• Employees: 18,000
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 3933

Financial Performance

In 2025, HKG:3933's revenue was 13.21 billion, a decrease of -3.99% compared to the previous year's 13.76 billion. Earnings were 2.09 billion, a decrease of -21.57%.

Financial numbers in CNY

Analyst Summary

According to 9 analysts, the average rating for 3933 stock is "Strong Buy." The 12-month stock price target is $15.64, which is an increase of 85.53% from the latest price.

Price Target

$15.64

(85.53% upside)

Analyst Consensus: Strong Buy